
Our Innovative Projects
PDX/O Oncology Platform
InnoSer has many collaborative projects with research groups from both academia and industry settings to develop novel technologies for use in preclinical settings. This includes a project executed in partnership with Vrije Universiteit Brussel and in close collaboration with Jessa Hospital in Hasselt, Belgium, and Leiden University Medical Center (LUMC, the Netherlands) that resulted in the development of an integrated PDXO drug screening platform. This platform consists of two complementary components, patient-derived xenografts (PDX) and patient-derived organoids (PDO), which are characterized in the same manner. Such models resemble the original patient-derived tumour both phenotypically and genetically. For this reason, one of the main advantages of such a platform is its predictive value in drug screening, as your compounds can be coherently tested both in vitro and in vivo, using the same starting parental material.
Many xenografts, organoids or combined models are already validated and currently available for compound testing. For other models, we are happy to collaborate and validate the platform with your compounds.
Want to read more?
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
As part of our ongoing efforts to support the development of new therapeutics for rare genetic neurological diseases, we are proud to introduce a new preclinical research model for Angelman Syndrome within InnoSer’s portfolio. In collaboration with Professor Ype...
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model. This collaboration aims to empower leading biotech and pharma innovators to perform rigorous studies informing clinical trial readiness of...
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...